Experimental animal and clinical studies have well established the association of prenatal exposure to diethylstilbestrol (DES) and the subsequen t development of reproductive tract abnormalities, including poor reproductive outcome and neoplasia. Overwhelmingly, the focus has been on DESinduced epithelial lesions, particularly vaginal adenosi s and adenocarcinoma ; however, uterine smooth muscle cells are also recognized as cellular targets of DES. This descriptive report characterizes uterine leiomyomas that occur in outbred CD-1 mice following exposure to DES prenatally on days 9 to 16 of gestation or on neonatal days 1 to 5. These DES-induced uterine leiomyomas have typical histomorphologic , and some immunohistochemica l characteristics of spontaneousl y occurring uterine smooth muscle tumors of B6C3F1 mice previousl y described in our laboratory, and they are also similar to uterine leiomyomas ( broids) commonl y observed in premenopausa l women.
INTRODUCTION
Uterine leiomyomas ( broids, myomas) are the most common gynecologic tumor in American women over 30 years of age, clinically affecting at least 25% of the population during their reproductive years (8) . Although leiomyomas are considered benign smooth muscle tumors, they may be associated with considerable morbidity (7, 8) . Despite the frequency with which uterine leiomyomas occur, little information is available in regard to their etiology; however, their dependence on steroid hormones suggests that altered responsiveness to these hormones, particularly estrogens, plays a critical role in their development.
There are concerns regarding the role of chemicals in the environment that possess estrogenic and/or endocrinedisrupting activity and their possible contributions to increased incidences of various diseases in hormone target tissues (4) (5) (6) 16) . The effects of these endocrine active compounds, especially those that bioaccumulate, are thought to be associated with decreased sperm quality and quantity, benign prostatic hyperplasia, prostatic and testicular cancer in males, and increases in breast cancer, endometriosis, and uterine leiomyomas ( broids) and adenocarcinomas in females (5, 6) . It remains to be determined whether exposure to these chemicals at ambient environmental levels is related to human disease. Ample evidence exists in both human and experimental animals to link developmental exposure to pharmacological levels of the synthetic estrogenic compound diethylstilbestrol (DES) with poor reproductive outcome and tumors later in life (12, 13, 17, 18, (20) (21) (22) (23) 25) .
For many years, much research has centered on the study of the effects of DES and other estrogens on differentiating reproductive tract tissues. Using the CD-1 outbred mouse, we have shown that benign and malignant changes in the developmentally DES-exposed murine genital tract closely resemble the human situation (for review, see 20, 23) . In fact, this DES animal model has both duplicated and predicted lesions observed in similarly exposed humans (20, 23) . The etiology of the various DES-induced abnormalities has remained unclear. Although many of the alterations are considered teratogenic changes (20, 24) , the pathogenesis of some of the lesions, especially those with neoplastic potential, is more dif cult to discern (21) . DES and other estrogens are known to be tumorigenic in humans and rodents (12) , however, the mechanism(s) by which these hormones induce lesions are only partially understood. Typically, studies focusing on DES-induced tumorigenesis have involved epithelial lesions of the uterus, vagina, and oviduct. However, alterations in smooth muscle cells following developmental DES treatment have also been reported by numerous laboratories (2, 3, 17) . Exogenous administration of estrogen has been associated with the development of uterine leiomyomas in guinea pigs (26) . Retrospectively, we have evaluated the myometrium of groups of mice that had been treated prenatally or neonatally with DES and have found uterine leiomyomas occurring in approximately 9% of those treated. In this paper, we describe some of the histomorphologic and immunohistochemical characteristics of these tumors.
MATERIALS AND METHODS
As previously described (17) , adult CD-1 [Cr1:CS-1 (ICR) BR] mice were obtained from Charles River Breeding Laboratories, Raleigh, NC, and bred to male mice of the same strain in the breeding facility at the National Institute of Environmental Health Sciences (NIEHS). Vaginal plug detection 611 0192-6233/02$3.00 $0.00 was considered day 0 of pregnancy. On day 9 of gestation, pregnant female mice were individually housed in cages with hardwood chip bedding and a cotton-ber-nesting block. Pregnant mice were housed under controlled lighting (12 hours light and 12 hours dark) and controlled temperature (21-22 C) conditions. NIH-31 lab mouse chow (Zeigler Brothers, Inc, Gardners, PA) and fresh reverseosmosis/deionized water were supplied ad libitum. All animal procedures complied with The National Institutes of Health (NIH)/NIEHS animal care guidelines.
Prenatal Treatment
DES (Sigma Chemical Co, St. Louis, MO) dissolved in corn oil or corn oil alone (Control) was administered as a subcutaneous injection to the pregnant dam on days 9 through 16 of gestation at a daily dose of 2.5, or 10 l g/kg of maternal body weight (Prenatal DES-2.5, Prenatal DES-10) as described previously (17) . Pregnant mice delivered their young on day 19 of gestation. At delivery, all litters were standardized to 8 pups per dam. Mice were euthanized at 13 or 17 months of age and tissues were evaluated for histologic changes.
Neonatal Treatment
Untreated pregnant mice delivered their young and litters were standardized to eight female pups. Pups were subcutaneously injected once daily with DES dissolved in corn oil (2 l g DES/pup/day; weight of pups ranged from 1 g on day 1 to 3.5 g on day 5) or corn oil alone (Control) on days 1 through 5 of life (Neonatal DES) as described (21) . All mice were weaned at 3 weeks of age and housed 4 per cage. Mice were euthanized at 12 or 18 months of age and tissues were evaluated for histologic changes.
Identi cation of Tumors and Tissue Preparation
Nine benign uterine smooth muscle cell tumors (leiomyomas) were identi ed in 7 adult CD-1 mice treated prenatally (n 52) or neonatally (n 27) with diethylstilbestrol (DES) ( Table 1) .
Tissues were xed in 10% neutral buffered formalin and paraf n-embedded. Sections of the uterus and uterine tumors were cut at 6 l m, and were mounted onto poly-L-lysine coated Fisher Probe-On glass slides (Histology Control Systems, Glen Head, NY). Glass slides, each containing sections of uterus or uterine tumors, were stored at room temperature in dust-free slide boxes until time of immunohistochemical staining. Tumors, also were stained with hematoxylin and eosin (H&E) for routine light microscopic evaluation. A Masson's trichrome special stain was done to con rm the smooth muscle cell origin of the uterine leiomyomas.
Transforming Growth Factor-Alpha (TGF-a ) Immunohistochemistry
A rabbit polyclonal antiserum against rat TGF-a (Peninsula Laboratories, Incorporated, Belmont, CA) was used to detect the localization of TGF-a in the tissue sections. Appropriate controls were used as we have previously described (1). 
Epidermal Growth Factor Receptor (EGF-R) Immunohistochemistry
To detect EGF-R in the tissues, an Oncogene Science kit (Oncogene Science, Uniondale, NY) consisting of a blocking reagent (normal goat serum), primary antibody (rabbit anti-EGF-R synthetic peptide; 1 mg/ml), secondary antibody (biotinylated goat anti-rabbit), and label (avidin-biotin horseradish peroxidase) was used. The procedure used was essentially similar to that used for TGF-a immunohistochemical staining: however, a lead antigen retrieval technique was also used (1, 11) .
Mouse skin was used as the positive control. Rat stomach and mouse esophagus were also found to express the EGF-R. Antibody speci city was tested by preabsorbing 50 l l of the diluted (1 l g/ml) primary antibody with a 10-fold excess of the EGF-R protein (5 l g/ml) (Oncogene Science, Uniondale, NY) for 30 minutes (at room temperature). Once antibody speci city was veri ed, tissues were stained similarly to that described previously (19) .
Proliferating Cell Nuclear Antigen (PCNA) Immunohistochemistry
Detection of replicating cells was done with an immunohistochemical method previously described by Greenwell et al. (11) . A modi cation of this method was employed using Mayer's hematoxylin (Polyscienti c Research and Development Corporation, Bay Shore, NY) as the counter stain for 30 seconds. In addition, tissue samples were incubated with the primary antibody for 30 minutes. Mouse intestine was used as the positive control.
PCNA Labeling Indices
Using image analysis (NIH Image v 1.54, NIH Bethesda, MD, 1994) and light microscopy, a 40 objective was used for quantitation of PCNA labeling indices (LI). One thousand nuclei of labeled and unlabeled tumor cells in the uterine leiomyomas were counted. Nuclei that stained brown to black were considered as positive staining nuclei. nuclei by the total number of cells (labeled and unlabeled), and multiplying by one hundred.
RESULTS

H&E Characteristics of Tumors
Each mouse had 1 or 2 (in the prenatally exposed mice only) well-demarcated and discrete uterine leiomyomas located primarily within the horns of the uterus (Figure 1) . Histologically, the leiomyoma cells were spindle shaped with elongated blunted nuclei typical of smooth muscle cells (Figure 2) . The tumor cells formed characteristic fasciculi that resembled the unaffected myometrial cells. Two tumors in 2 prenatally treated mice (2.5 l g/kg or 10 l g/kg) of DES, and 1 tumor in a neonatally treated mouse had focal regions of cellular atypia characterized by cells with hyperchromatic rounded nuclei, some with prominent nucleoli, increased mitotic activity, and rounding of cytoplasmic spindled shape. Red staining of leiomyoma tumor cells with a Masson's trichrome stain con rmed the smooth muscle origin of the tumors (Figure 3 ).
TGF-a and EGF-R Immunohistochemistry
TGF-a was present in 4/9 tumors and was expressed at weak to moderate levels within the cytoplasm of the leiomyoma smooth muscle cells (Table 1 ; Figure 4 ). The tumors that expressed TGF-a also showed weak to moderate cytoplasmic immunoexpression of EGF-R (Table 1; Figure 4) . With the exception of 1 small tumor, the TGF-a -positive tumors had focal regions of cellular atypia as described earlier. 
PCNA Immunohistochemistry and Tumor Diameter Size
The labeling indices ranged from 0.0-5.9% and there was no correlation between tumor size or degree of atypia and PCNA labeling.
DISCUSSION
Research, for many years, has centered upon studying the effects of DES and other estrogens on differentiating reproductive tract tissues. Using the CD-1 outbred mouse, it has been shown that benign and malignant changes in the developmentally DES-exposed murine genital tract closely parallel those seen in humans (20, 23) . Although most studies have focused on the characterization of epithelial alterations including vaginal and uterine adenocarcinoma (21, 22) , perinatal exposure to DES is also associated with a high incidence of smooth muscle changes in the uterus, and a low, but signi cant, increased incidence in smooth muscle tumors. In this study, approximately 9% of the mice had uterine leiomyomas, but this number may rise because we are currently screening more mice treated with lower doses of DES. Our earlier ndings suggest that the highest dose of 100 l g/kg was often teratogenic and caused smooth muscle hypoplasia and underdevelopment, and thus no leiomyomas (17) . However, doses lower than 100 l g/kg caused smooth muscle hyperplasia, accompanied by occasional leiomyomas. There were no uterine leiomyomas observed in the control mice in this study. The historical control incidence of uterine leiomyomas in Crl:CD-1 mice at 18 months of age is 1.70% (Charles River Laboratories, 1995, www.criver.com ). In this study, most of the uterine tumors present in the DES-exposed mice had typical histologic characteristics of uterine leiomyomas observed in women. The tumors were multiple in 29% of the mice and tumor multiplicity is commonly observed in women with uterine leiomyomas.
We observed a few tumors with areas of atypia. With the exception of one small tumor, the tumors with focal atypia showed increased cytoplasmic expression of TGFa and EGF-R. This is similar to our ndings in B6C3F1 mice in that TGF-a was not expressed in the uterine leiomyomas; however, this growth factor was expressed in the uterine leiomyosarcomas (19) . TGF-a has been shown to transform broblasts into a malignant phenotype, therefore suggesting that overexpression of TGF-a may be important in malignant transformation of mesenchymal cells (27) . In the DESinduced uterine leiomyomas, we observed that only those tumors showing focal areas of atypia expressed TGF-a . These data suggest that TGF-a expression may be an early and necessary event for malignant transformation. Conversely, overtly benign tumors showing no histologic evidence of cellular atypia did not express TGF-a , a nding that has been reported for B6C3F1 mice and human uterine leiomyomas (10, 19) .
In this study, there was no correlation between PCNA labeling and atypia, or PCNA labeling and TGF-a or EGF-R expression in the leiomyomas with atypia. In an earlier study we conducted using B6C3F1 mice, the uterine smooth muscle tumors were clearly benign or malignant and one could nicely correlate the expression of TGF-a and EGF-R and PCNA (19) . Also, the tumors were thought to be nontreatmentrelated and spontaneous in nature. However, in this study, the tumors were clearly induced by a synthetic estrogen and DES exposure occurred during early uterine development. Whether the hormonal properties of DES and/or early exposure of the developing uterus to a synthetic estrogen play a role in the lack of correlation between the proliferative responses we observed in this study and growth factor/receptor expression and atypia are unknown. It should be noted that DES exposure has been associated with microtubule disruption and dysfunction of the mitotic apparatus in cultured Syrian hamster embryo (SHE) cells (28), and we have found that neonatal exposures to high doses of CD-1 mice can result in lowered proliferative activity of uterine cell types (29) . The relationship of the size of the DES-induced leiomyomas to their PCNA labeling index was also explored in this study. We found no signi cant relationship between the size of a tumor and its proliferative state on the basis of any of PCNA labeling data. In women, it also has been found that there is no statistically signi cant correlation between uterine leiomyoma size and proliferative state of the tumor (9) .
These results with DES exposure support the hypothesis that exposure to endocrine-active compounds during development may, indeed, contribute to the occurrence of uterine leiomyomas ( broids) later in life. The DES-induced uterine leiomyomas in CD-1 mice have histomorphologic features similar to broids observed in women. In addition, the induction of multiple uterine smooth muscle tumors in some of the mice following perinatal DES exposure is analogous to tumor multiplicity commonly observed in women with broids.
